Investors Alert: Humacyte, Inc. Faces Class Action Over Alleged Securities Fraud

LOS ANGELES, Dec. 19, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) has announced that investors suffering significant losses may lead a class action lawsuit against Humacyte, Inc. (“Humacyte” or the “Company”) HUMA.

Class Period: May 10, 2024 – October 17, 2024
Lead Plaintiff Deadline: January 17, 2025

Investors interested in leading the Humacyte lawsuit can submit their contact information at www.glancylaw.com/cases/Humacyte-Inc/. Additionally, they can reach out to Charles H. Linehan from GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com for more information about their rights.

The filed complaint claims that, during the Class Period, Defendants neglected to inform investors about key issues, including: (1) the Company’s facility in Durham, North Carolina not complying with good manufacturing practices relating to quality assurance and microbial testing; (2) delays in the FDA’s review of the BLA while Humacyte addressed these problems; and (3) significant risks to FDA approval of ATEV for vascular trauma stemming from these issues. Consequently, the Defendants’ positive claims about the Company’s operations were misrepresentations that lacked a reasonable basis.

For updates, follow us on LinkedIn, Twitter, or Facebook.

To be a participant in the class action, no immediate actions are required. Investors can either choose their own legal representation or remain an absent member of the action. For further details about this lawsuit or if you have any related inquiries, please contact Charles Linehan, Esquire, of GPM, located at 1925 Century Park East, Suite 2100, Los Angeles, California 90067 or call 310-201-9150, Toll-Free at 888-773-9224, or email shareholders@glancylaw.com. If emailing, include your mailing address, telephone number, and number of shares purchased.

This press release may constitute Attorney Advertising in some jurisdictions, according to local laws and ethical standards.

Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/huma-investors-have-opportunity-to-lead-humacyte-inc-securities-fraud-lawsuit-302336486.html

SOURCE Glancy Prongay & Murray LLP